|April 9, 2014|
|08:03 EDT||LLY||Eli Lilly and T1D to partner in diabetes research collaboration|
Eli Lilly and T1D Exchange have entered into a research collaboration about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes. The collaboration will involve multiple projects over an initial five-year period. The first project of the collaboration will assess user experience associated with insulin pumps and multiple daily injections. Following the survey, a study of clinic registry participants is planned, to further shed light on how insulin pumps are used and how multiple daily injections occur in real-world practice.
News For LLY From The Last 14 Days
Check below for free stories on LLY the last two weeks.
|August 28, 2014|
|07:31 EDT||LLY||Eli Lilly management to meet with Deutsche Bank|
Subscribe for More Information
|August 27, 2014|
|09:53 EDT||LLY||On The Fly: Analyst Initiation Summary|
Bristol-Myers (BMY) initiated with a Hold at Deutsche Bank... ASML (ASML) initiated with a Hold at Stifel... Akamai (AKAM) initiated with an Outperform at RW Baird... Concur (CNQR) initiated with a Neutral at DA Davidson... CyrusOne (CONE) initiated with a Neutral at Citigroup... Eli Lilly (LLY) initiated with a Buy at Deutsche Bank... Garmin (GRMN) initiated with a Neutral at RW Baird... Merck (MRK) initiated with a Hold at Deutsche Bank... NetSuite (N) initiated with a Buy at DA Davidson... Oracle (ORCL) initiated with a Neutral at DA Davidson... Oxford Industries (OXM) initiated with a Buy at Wunderlich... Pfizer (PFE) initiated with a Buy at Deutsche Bank... ServiceNow (NOW) initiated with a Buy at DA Davidson... Workday (WDAY) initiated with a Neutral at DA Davidson... MannKind (MNKD) initiated with a Buy at Jefferies... STMicroelectronics (STM) initiated with an Underperform at Credit Suisse... Kirkland's (KIRK) initiated with an Outperform at Barrington.
|06:42 EDT||LLY||Eli Lilly initiated with a Buy at Deutsche Bank|
|August 26, 2014|
|09:07 EDT||LLY||Eli Lilly announces Jardiance available in U.S. pharmacies|
Subscribe for More Information
|August 21, 2014|
|07:12 EDT||LLY||Eli Lilly announces results from pivotal UNCOVER studies for ixekizumab |
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.